A Phase 3 interventional study of DTG 50 mg and EFV 600 mg in Infection, Human Immunodeficiency Virus and HIV Infections, sponsored by ViiV Healthcare. Completed at 28 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-12.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
HIV/Tuberculosis (TB) co-infection have profound effects on the host's immune system. TB is the most common cause of death in patients with HIV worldwide. Rifamycins (such as rifampicin [RIF]) are an important component of TB therapy because of their unique activity. The problem is that most protease inhibitors (PI) and non-nucleoside reverse transcriptase inhibitors (NNRTI) used to treat HIV have significant drug-drug interactions with RIF that can lead to reduced concentrations of these agents with risk of treatment failure or resistance. The non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (EFV) does not present the same significant drug interactions with RIF. EFV-based HIV treatment was tested in patients concomitantly treated with RIF-containing TB therapy, demonstrating that their co-administration can be used safely and effectively. However, the side effect profile of EFV overlaps with the RIF-containing TB regimens and makes the management of treatment toxicities very complex. Integrase inhibitors (INI), such as dolutegravir (DTG), may offer an important alternative to EFV-based therapy in TB coinfected patients. A Phase I drug-drug interaction study was conducted in healthy, HIV-seronegative subjects, and showed that DTG at 50 mg twice daily given together with RIF was well-tolerated and resulted in DTG concentrations similar to those of DTG 50 mg given once daily alone, which is the recommended dose for INI-naive patients. Therefore, ART regimens using DTG 50 mg twice daily may represent a new treatment option for TB-infected patients who require concurrent treatment for HIV infection. This is a Phase III b, randomized, open-label study describing the efficacy and safety of DTG and EFV-containing ART regimens in HIV/TB co-infected patients. This study is designed to assess the antiviral activity of DTG or efavirenz (EFV) ART-containing regimens through 48 weeks. A total of approximately 115 +/-5% subjects will be randomly assigned in a 3:2 ratio to DTG (approximately 69 subjects) and EFV (approximately 46 subjects), respectively. This study will include a Screening Period, a Randomized Phase (Day 1 to 48 weeks plus a 4-week extension), and a DTG Open-label extension (OLE). During the DTG OLE, subjects will be supplied with DTG until it is locally approved and commercially available, the subject no longer derives clinical benefit, or the subject meets a protocol-defined reason for discontinuation, which ever comes first.
2,096 studies on the registry are indexed under Infections; 364 are open to participants now.
This study's enrollment of 113 is close to the median of 113 across 1,304 interventional studies indexed under Infections.
Browse Infections studies →ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Twice-daily DTG 50 mg plus dual NRTI during RIF-containing TB treatment (isoniazid, RIF, pyrazinamide and ethambutol standard doses by the NTP under program conditions or acceptable alternative RIF-containing regimens) and for 2 weeks following discontinuation of TB treatment, then once-daily DTG 50 mg with the same NRTI through Week 52
Drug: DTG 50 mg
Once-daily EFV 600 mg plus dual NRTI through Week 52 along with TB treatment including isoniazid, RIF, pyrazinamide and ethambutol standard doses by the NTP under program conditions.
Drug: EFV 600 mg
DTG is available as 50 mg film-coated tablet. DTG may be administered with or without food
EFV is supplied as film-coated capsule-shaped oral tablet containing 600 mg of EFV and must be administered without food
Percentage of Participants With Plasma Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/Milliliter at Week 48 in DTG Arm Using the Modified United States (US) Food and Drug Administration (FDA) Snapshot Algorithm
Plasma samples were collected for quantitative analysis of HIV-1 RNA. The percentage of participants with plasma HIV-1 RNA \<50 copies/milliliter was assessed at Week 48 using the snapshot algorithm in the DTG arm. Response was assessed using a modified FDA Snapshot algorithm in which participants were not penalized for any single protocol allowed background therapy substitution even if occurs after the first trial visit. In this approach participants with HIV-1 RNA \>=50 copies/milliliter are considered as non-responders. Participants without HIV-1 RNA data at Week 48 (due to missing data or discontinuation of investigational product \[IP\] prior to visit window) are also considered as non-responders, as well as participants with anti-retroviral (ART) substitutions were not permitted. Study drug (i.e. DTG or EFV) was not allowed to be substituted.
Time frame: Week 48
Percentage of Participants With Plasma HIV-1 RNA <50 Copies/Milliliter at Week 48 in EFV Arm Using the Modified Snapshot Algorithm
Plasma samples were collected for quantitative analysis of HIV-1 RNA. The percentage of participants with plasma HIV-1 RNA \<50 copies/milliliter were assessed at Week 48 using the snapshot algorithm in the EFV arm. Response was assessed using a modified FDA Snapshot algorithm in which participants were not penalized for any single protocol allowed background therapy substitution even if occurs after the first trial visit. In this approach participants with HIV-1 RNA \>=50 copies/milliliter are considered as non-responders. Participants without HIV-1 RNA data at Week 48 (due to missing data or discontinuation of IP prior to visit window) are also considered as non-responders, as well as participants with ART substitutions were not permitted. Study drug (i.e. DTG or EFV) was not allowed to be substituted.
Time frame: Week 48
Percentage of Participants With Plasma HIV-1 RNA <50 Copies/Milliliter at Week 24 in Both EFV and DTG Arms Using the Modified Snapshot Algorithm
Plasma samples were collected for quantitative analysis of HIV-1 RNA. The percentage of participants with plasma HIV-1 RNA \<50 copies/milliliter were assessed at Week 24 using the snapshot algorithm in the DTG and EFV arm. Response was assessed according to the Modified Snapshot algorithm. In this approach participants with HIV-1 RNA \>=50 copies/milliliter were considered non-responders. Participants without HIV-1 RNA data at Week 24 (due to missing data or discontinuation of IP prior to visit window) were also considered as non-responders, as well as participants with ART substitutions were not permitted. Substitution of a background NRTI agent was permissible one time if it was due to reasons of drug toxicity.
Time frame: Week 24
Percentage of Participants Without Confirmed Virologic Withdrawal and Without Discontinuation Due to Treatment-related Reasons at Week 24 and Week 48
Percentage of participants not meeting confirmed virologic withdrawal criteria nor discontinued due to treatment related reasons at the time of analysis at Week 24 (through Day 210) and Week 48 (through Day 350) has been presented by treatment group. The time to meeting confirmed virologic withdrawal criteria or discontinuation due to treatment related reasons (i.e., discontinuation due to drug-related adverse event \[AE\], or due to protocol defined safety stopping criteria, or due to lack of efficacy) were calculated. Participants who met confirmed virologic withdrawal criteria or discontinuation due to treatment related reasons were considered as Failure. Participants who had not met confirmed virologic withdrawal criteria (per protocol) and were ongoing in the study, or who had discontinued for reasons other than those related to treatment, were censored. This would be the Treatment-Related Discontinuation = Failure (TRDF) data.
Time frame: Week 24 and Week 48
Change From Baseline in Cluster of Differentiation 4 (CD4+) Counts at Week 24 and Week 48
Blood samples were collected for assessment of lymphocyte subsets (CD4+ lymphocyte count) by flow cytometry at Baseline and Weeks 24, 48. Baseline was defined as the last pre-treatment value observed (typically from Day 1 visit). Change from Baseline was calculated subtracting the value at the specified time point from the Baseline value.
Time frame: Baseline (Day 1), Week 24 and Week 48
Number of Participants With Serious Adverse Event (SAE) and Common (>=5%) Non-serious AE (Non-SAE) - Randomized Phase
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward medical occurrence that, at any dose that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, all events of possible drug-induced liver injury with hyperbilirubinemia or any other situation according to medical or scientific judgment. Data for number of participants with SAE and common (\>=5%) non-SAE over 52 weeks has been summarized.
Time frame: Up to Week 52
Number of Participants With SAE and Common (>=5%) Non-SAE - OLE Phase
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward medical occurrence that, at any dose that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, all events of possible drug-induced liver injury with hyperbilirubinemia or any other situation according to medical or scientific judgment. Data for number of participants with SAE and common (\>=5%) non-SAE from Week 52 to Week 252 has been summarized.
Time frame: Week 52 to Week 252
Number of Participants With Maximum Post-Baseline-emergent Chemistry Toxicities - Randomized Phase
Blood samples for assessment of clinical chemistry parameters were collected at indicated time points. Clinical chemistry assessments included alanine aminotransferase (ALT), albumin, alkaline phosphatase, aspartate aminotransferase (AST), bilirubin, carbon dioxide, cholesterol, creatine kinase, creatinine, glucose, low density lipoprotein (LDL) cholesterol calculation, lipase, phosphate, potassium, and sodium. Data for number of participants who experienced maximum post-Baseline emergent chemistry toxicities were summarized. Maximum post-Baseline emergent chemistry toxicities were graded using Division of Acquired Immune Deficiency Syndrome (DAIDS) toxicity grading for HIV-infected participants as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life-threating). Higher grade indicates more severity.
Time frame: Up to Week 52
Number of Participants With Maximum Post-Baseline-emergent Chemistry Toxicities- Randomized Phase + OLE Phase
Blood samples for assessment of clinical chemistry parameters were collected at indicated time points. Clinical chemistry assessments included ALT, albumin, alkaline phosphatase, AST, bilirubin, carbon dioxide, cholesterol, creatine kinase, creatinine, glucose, LDL cholesterol calculation, lipase, phosphate, potassium, and sodium. Data for number of participants with maximum post-Baseline emergent chemistry toxicities were summarized. Maximum post-Baseline emergent chemistry toxicities were graded using DAIDS toxicity grading for HIV-infected participants as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life-threating) . Higher grade indicates more severity.
Time frame: Up to Week 252
Number of Participants With Maximum Post-Baseline-emergent Hematology Toxicities- Randomized Phase
Blood samples for assessment of hematology parameters were collected at indicated time points. Hematology assessments included hemoglobin, leukocytes, neutrophils and platelets. Data for number of participants who experienced maximum post-Baseline emergent hematology toxicities were summarized. Maximum post-Baseline emergent hematology toxicities were graded using DAIDS toxicity grading for HIV-infected participants as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life-threating). Higher grade indicates more severity.
Time frame: Up to Week 52
Number of Participants With Maximum Post-Baseline-emergent Hematology Toxicities - Randomized Phase + OLE Phase
Blood samples for assessment of hematology parameters were collected at indicated time points. Hematology assessments included hemoglobin, leukocytes, neutrophils and platelets. Data for number of participants who experienced maximum post-Baseline emergent hematology toxicities were summarized. Maximum post-Baseline emergent hematology toxicities were graded using DAIDS toxicity grading for HIV-infected participants as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life-threating). Higher grade indicates more severity.
Time frame: Up to Week 252
Percent Change From Baseline in the Fasting Lipid Profile at Week 24 and Week 48
Samples for lipid measurements were obtained in a fasted state at Baseline, Week 24 and Week 48. The parameters assessed during the lipid profile were total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, triglycerides. Baseline was defined as the last pre-treatment value observed (typically from Day 1 visit). Percent change from Baseline for a parameter was calculated as the observed value minus the Baseline value divided by Baseline value multiplied by 100. Data for fasting lipid parameters has been summarized.
Time frame: Baseline (Day 1), Week 24 and Week 48
Change From Baseline in the Fasting Lipid Profile for Total Cholesterol/HDL Ratio at Week 24 and Week 48
Samples for lipid measurements were obtained in a fasted state at Baseline, Week 24 and Week 48. The parameter assessed during the lipid profile was total cholesterol/HDL ratio. Baseline was defined as the last pre-treatment value observed (typically from Day 1 visit). Change from baseline for a parameter was calculated as the observed value minus the Baseline value.
Time frame: Baseline (Day 1), Week 24 and Week 48
Percentage of Participants Who Permanently Discontinued Study Treatment Due to AEs - Randomized Phase
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Data for percentage of participants who permanently discontinued study treatment due to any AE over 52 weeks has been summarized.
Time frame: Up to Week 52
Percentage of Participants Who Permanently Discontinued Study Treatment Due to AEs - OLE Phase
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Data for percentage of participants who permanently discontinued study treatment due to any AE from Week 52 to Week 252 has been summarized.
Time frame: Week 52 to Week 252
Number of Participants With Tuberculosis (TB) Associated (Assoc.) Immune Reconstitution Inflammatory Syndrome (IRIS)
Participants were monitored for signs and symptoms of TB-assoc. IRIS. Participants with IRIS symptoms in any AE or HIV assoc. conditions were classified by Endpoint Adjudication Committee in following four categories: met criteria for TB-assoc. IRIS, possibly met criteria for TB-assoc. IRIS, suspected TB-assoc. IRIS but not possible to adjudicate and No TB associated IRIS. They were further graded from Grades 1 to 4 using DAIDS. Higher grade indicates more severity. The preliminary requirements to meet TB-assoc. IRIS criteria were diagnosis of TB and initial response to TB treatment (stabilized or improved condition of participant in presence of TB treatment before starting ART). The clinical criteria was onset of IRIS signs and symptoms related to TB should occur within first 3 months of starting, restarting or changing ART regimen for treatment failure. Number of participants who sent to the adjudication committee and analyzed were presented.
Time frame: Up to Week 12
Number of Participants With Treatment-emergent Genotypic Resistance
Whole venous blood samples were obtained from each participant until Week 52 for potential viral genotypic and phenotypic analyses. Genotypic and phenotypic testing was conducted for participants meeting confirmed virologic withdrawal criteria, i.e., confirmed HIV-1 RNA \>=400 copies/milliliter from Week 24 onwards. Genotypic and phenotypic analyses was carried out by Monogram Biosciences using, but not limited to, their Standard Phenosense and GenoSure testing methods for protease (PRO), reverse transcriptase (RT), and integrase assays. Data for number of participants with treatment-emergent genotypic resistance mutations have been presented for the RT region on codons G190G, K101K, K103K, K65K, V106V and Y181Y.
Time frame: Up to Week 52
Number of Participants With Treatment-emergent Phenotypic Resistance
Phenotypic susceptibility to all licensed antiretroviral drugs, including DTG and EFV were determined using PhenoSense HIV assays from Monogram Inc. Clinical cutoffs or biological cutoffs by PhenoSense were used to define the phenotypic susceptibility of background treatment and were interpreted as fold change \> clinical lower cut-off or biologic cut-off as resistance, fold change \<=clinical lower cut-off or biologic cut-off as sensitive, and fold change \> clinical higher cut-off as resistance, fold change \<=clinical higher cut-off and \> clinical lower cut-off as partially sensitive, and fold change \<=clinical lower cut-off as sensitive. Data has been presented for participants with treatment-emergent phenotypic resistance.
Time frame: Up to Week 52
This study was conducted in 7 countries across 25 centers; Argentina (2), Brazil (4), Mexico (3), Peru (4), Russia (2), South Africa (8) and Thailand (2). Participants were randomized to receive either Dolutegravir (DTG) or Efavirenz (EFV) containing regimens.
| Milestone | DTG 50 mg | EFV 600 mg |
|---|---|---|
| Started | 69 | 44 |
| Completed | 50 | 35 |
| Not completed | 19 | 9 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Lack of efficacy | 1 | 1 |
| Withdrew: Protocol violation | 3 | 2 |
| Withdrew: Withdrawal by subject | 3 | 1 |
| Withdrew: Lost to follow-up | 11 | 3 |
| Withdrew: Physician decision | 1 | 0 |
| Milestone | DTG 50 mg | EFV 600 mg |
|---|---|---|
| Started | 47 | 19 |
| Completed | 35 | 16 |
| Not completed | 12 | 3 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Withdrawal by subject | 4 | 1 |
| Withdrew: Reached protocol defined stopping criteria | 2 | 0 |
| Withdrew: Lost to follow-up | 3 | 1 |
Plasma samples were collected for quantitative analysis of HIV-1 RNA. The percentage of participants with plasma HIV-1 RNA \<50 copies/milliliter was assessed at Week 48 using the snapshot algorithm in the DTG arm. Response was assessed using a modified FDA Snapshot algorithm in which participants were not penalized for any single protocol allowed background therapy substitution even if occurs after the first trial visit. In this approach participants with HIV-1 RNA \>=50 copies/milliliter are considered as non-responders. Participants without HIV-1 RNA data at Week 48 (due to missing data or discontinuation of investigational product \[IP\] prior to visit window) are also considered as non-responders, as well as participants with anti-retroviral (ART) substitutions were not permitted. Study drug (i.e. DTG or EFV) was not allowed to be substituted.
| Percentage of participants | DTG 50 mg |
|---|---|
| Percentage of Participants With Plasma Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/Milliliter at Week 48 in DTG Arm Using the Modified United States (US) Food and Drug Administration (FDA) Snapshot Algorithm | 75 (65 to 86) |
Plasma samples were collected for quantitative analysis of HIV-1 RNA. The percentage of participants with plasma HIV-1 RNA \<50 copies/milliliter were assessed at Week 48 using the snapshot algorithm in the EFV arm. Response was assessed using a modified FDA Snapshot algorithm in which participants were not penalized for any single protocol allowed background therapy substitution even if occurs after the first trial visit. In this approach participants with HIV-1 RNA \>=50 copies/milliliter are considered as non-responders. Participants without HIV-1 RNA data at Week 48 (due to missing data or discontinuation of IP prior to visit window) are also considered as non-responders, as well as participants with ART substitutions were not permitted. Study drug (i.e. DTG or EFV) was not allowed to be substituted.
| Percentage of participants | EFV 600 mg |
|---|---|
| Percentage of Participants With Plasma HIV-1 RNA <50 Copies/Milliliter at Week 48 in EFV Arm Using the Modified Snapshot Algorithm | 82 (70 to 93) |
Plasma samples were collected for quantitative analysis of HIV-1 RNA. The percentage of participants with plasma HIV-1 RNA \<50 copies/milliliter were assessed at Week 24 using the snapshot algorithm in the DTG and EFV arm. Response was assessed according to the Modified Snapshot algorithm. In this approach participants with HIV-1 RNA \>=50 copies/milliliter were considered non-responders. Participants without HIV-1 RNA data at Week 24 (due to missing data or discontinuation of IP prior to visit window) were also considered as non-responders, as well as participants with ART substitutions were not permitted. Substitution of a background NRTI agent was permissible one time if it was due to reasons of drug toxicity.
| Percentage of participants | DTG 50 mg | EFV 600 mg |
|---|---|---|
| Percentage of Participants With Plasma HIV-1 RNA <50 Copies/Milliliter at Week 24 in Both EFV and DTG Arms Using the Modified Snapshot Algorithm | 81 (72 to 90) | 89 (79 to 98) |
Percentage of participants not meeting confirmed virologic withdrawal criteria nor discontinued due to treatment related reasons at the time of analysis at Week 24 (through Day 210) and Week 48 (through Day 350) has been presented by treatment group. The time to meeting confirmed virologic withdrawal criteria or discontinuation due to treatment related reasons (i.e., discontinuation due to drug-related adverse event \[AE\], or due to protocol defined safety stopping criteria, or due to lack of efficacy) were calculated. Participants who met confirmed virologic withdrawal criteria or discontinuation due to treatment related reasons were considered as Failure. Participants who had not met confirmed virologic withdrawal criteria (per protocol) and were ongoing in the study, or who had discontinued for reasons other than those related to treatment, were censored. This would be the Treatment-Related Discontinuation = Failure (TRDF) data.
| Percentage of participants | DTG 50 mg | EFV 600 mg |
|---|---|---|
| Week 24 | 98.4 (89.1 to 99.8) | 95.2 (82.1 to 98.8) |
| Week 48 | 96.6 (87.0 to 99.1) | 92.7 (79.1 to 97.6) |
Blood samples were collected for assessment of lymphocyte subsets (CD4+ lymphocyte count) by flow cytometry at Baseline and Weeks 24, 48. Baseline was defined as the last pre-treatment value observed (typically from Day 1 visit). Change from Baseline was calculated subtracting the value at the specified time point from the Baseline value.
| Cells per millimeter^3 | DTG 50 mg | EFV 600 mg |
|---|---|---|
| Week 24, n=61,41 | 153.2 ± 125.09 | 127.1 ± 158.14 |
| Week 48, n=49, 33 | 199.0 ± 146.22 | 194.5 ± 137.81 |
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward medical occurrence that, at any dose that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, all events of possible drug-induced liver injury with hyperbilirubinemia or any other situation according to medical or scientific judgment. Data for number of participants with SAE and common (\>=5%) non-SAE over 52 weeks has been summarized.
| Participants | DTG 50 mg | EFV 600 mg |
|---|---|---|
| Common Non-SAE | 38 | 33 |
| SAE | 5 | 5 |
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward medical occurrence that, at any dose that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, all events of possible drug-induced liver injury with hyperbilirubinemia or any other situation according to medical or scientific judgment. Data for number of participants with SAE and common (\>=5%) non-SAE from Week 52 to Week 252 has been summarized.
| Participants | DTG 50 mg | EFV 600 mg |
|---|---|---|
| Common Non-SAE | 36 | 16 |
| SAE | 5 | 2 |
Blood samples for assessment of clinical chemistry parameters were collected at indicated time points. Clinical chemistry assessments included alanine aminotransferase (ALT), albumin, alkaline phosphatase, aspartate aminotransferase (AST), bilirubin, carbon dioxide, cholesterol, creatine kinase, creatinine, glucose, low density lipoprotein (LDL) cholesterol calculation, lipase, phosphate, potassium, and sodium. Data for number of participants who experienced maximum post-Baseline emergent chemistry toxicities were summarized. Maximum post-Baseline emergent chemistry toxicities were graded using Division of Acquired Immune Deficiency Syndrome (DAIDS) toxicity grading for HIV-infected participants as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life-threating). Higher grade indicates more severity.
| Participants | DTG 50 mg | EFV 600 mg |
|---|---|---|
| ALT, Grade 1 | 10 | 9 |
| ALT, Grade 2 | 1 | 1 |
| ALT, Grade 3 | 1 | 1 |
| ALT, Grade 4 | 0 | 0 |
| Albumin, Grade 1 | 2 | 2 |
| Albumin, Grade 2 | 8 | 1 |
| Albumin, Grade 3 | 0 | 0 |
| Albumin, Grade 4 | 0 | 0 |
| Alkaline phosphatase, Grade 1 | 7 | 11 |
| Alkaline phosphatase, Grade 2 | 0 | 1 |
| Alkaline phosphatase, Grade 3 | 0 | 0 |
| Alkaline phosphatase, Grade 4 | 0 | 0 |
| AST, Grade 1 | 11 | 8 |
| AST, Grade 2 | 4 | 3 |
| AST, Grade 3 | 0 | 0 |
| AST, Grade 4 | 1 | 1 |
| Bilirubin, Grade 1 | 3 | 3 |
| Bilirubin, Grade 2 | 1 | 0 |
| Bilirubin, Grade 3 | 0 | 0 |
| Bilirubin, Grade 4 | 0 | 0 |
| Carbon dioxide, Grade 1 | 14 | 8 |
| Carbon dioxide, Grade 2 | 4 | 4 |
| Carbon dioxide, Grade 3 | 1 | 0 |
| Carbon dioxide, Grade 4 | 0 | 0 |
| Cholesterol, Grade 1 | 5 | 6 |
| Cholesterol, Grade 2 | 1 | 2 |
| Cholesterol, Grade 3 | 0 | 0 |
| Cholesterol, Grade 4 | 0 | 0 |
| Creatine kinase, Grade 1 | 3 | 4 |
| Creatine kinase, Grade 2 | 0 | 0 |
| Creatine kinase, Grade 3 | 0 | 0 |
| Creatine kinase, Grade 4 | 1 | 1 |
| Creatinine, Grade 1 | 2 | 0 |
| Creatinine, Grade 2 | 0 | 0 |
| Creatinine, Grade 3 | 0 | 1 |
| Creatinine, Grade 4 | 0 | 0 |
| Glucose, Grade 1 | 11 | 10 |
| Glucose, Grade 2 | 3 | 5 |
| Glucose, Grade 3 | 0 | 0 |
| Glucose, Grade 4 | 0 | 0 |
| LDL cholesterol calculation, Grade 1 | 0 | 3 |
| LDL cholesterol calculation, Grade 2 | 1 | 0 |
| LDL cholesterol calculation, Grade 3 | 0 | 0 |
| LDL cholesterol calculation, Grade 4 | 0 | 0 |
| Lipase, Grade 1 | 2 | 2 |
| Lipase, Grade 2 | 0 | 2 |
| Lipase, Grade 3 | 0 | 0 |
| Lipase, Grade 4 | 0 | 1 |
| Phosphate, Grade 1 | 5 | 3 |
| Phosphate, Grade 2 | 3 | 5 |
| Phosphate, Grade 3 | 1 | 0 |
| Phosphate, Grade 4 | 0 | 0 |
| Potassium, Grade 1 | 5 | 3 |
| Potassium, Grade 2 | 0 | 2 |
| Potassium, Grade 3 | 0 | 0 |
| Potassium, Grade 4 | 1 | 1 |
| Sodium, Grade 1 | 17 | 9 |
| Sodium, Grade 2 | 2 | 3 |
| Sodium, Grade 3 | 1 | 0 |
| Sodium, Grade 4 | 0 | 0 |
Blood samples for assessment of clinical chemistry parameters were collected at indicated time points. Clinical chemistry assessments included ALT, albumin, alkaline phosphatase, AST, bilirubin, carbon dioxide, cholesterol, creatine kinase, creatinine, glucose, LDL cholesterol calculation, lipase, phosphate, potassium, and sodium. Data for number of participants with maximum post-Baseline emergent chemistry toxicities were summarized. Maximum post-Baseline emergent chemistry toxicities were graded using DAIDS toxicity grading for HIV-infected participants as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life-threating) . Higher grade indicates more severity.
| Participants | DTG 50 mg | EFV 600 mg |
|---|---|---|
| ALT, Grade 1 | 12 | 10 |
| ALT, Grade 2 | 3 | 2 |
| ALT, Grade 3 | 1 | 1 |
| ALT, Grade 4 | 0 | 0 |
| Albumin, Grade 1 | 2 | 2 |
| Albumin, Grade 2 | 8 | 1 |
| Albumin, Grade 3 | 0 | 0 |
| Albumin, Grade 4 | 0 | 0 |
| Alkaline phosphatase, Grade 1 | 8 | 12 |
| Alkaline phosphatase, Grade 2 | 0 | 1 |
| Alkaline phosphatase, Grade 3 | 0 | 0 |
| Alkaline phosphatase, Grade 4 | 0 | 0 |
| AST, Grade 1 | 14 | 8 |
| AST, Grade 2 | 6 | 3 |
| AST, Grade 3 | 1 | 1 |
| AST, Grade 4 | 1 | 1 |
| Bilirubin, Grade 1 | 7 | 3 |
| Bilirubin, Grade 2 | 1 | 0 |
| Bilirubin, Grade 3 | 0 | 0 |
| Bilirubin, Grade 4 | 0 | 0 |
| Carbon dioxide, Grade 1 | 16 | 10 |
| Carbon dioxide, Grade 2 | 5 | 4 |
| Carbon dioxide, Grade 3 | 1 | 0 |
| Carbon dioxide, Grade 4 | 0 | 0 |
| Cholesterol, Grade 1 | 5 | 6 |
| Cholesterol, Grade 2 | 1 | 2 |
| Cholesterol, Grade 3 | 0 | 0 |
| Cholesterol, Grade 4 | 0 | 0 |
| Creatine kinase, Grade 1 | 7 | 4 |
| Creatine kinase, Grade 2 | 1 | 1 |
| Creatine kinase, Grade 3 | 0 | 0 |
| Creatine kinase, Grade 4 | 2 | 1 |
| Creatinine, Grade 1 | 2 | 0 |
| Creatinine, Grade 2 | 1 | 0 |
| Creatinine, Grade 3 | 0 | 1 |
| Creatinine, Grade 4 | 0 | 0 |
| Glucose, Grade 1 | 12 | 12 |
| Glucose, Grade 2 | 7 | 5 |
| Glucose, Grade 3 | 0 | 0 |
| Glucose, Grade 4 | 0 | 0 |
| LDL cholesterol calculation, Grade 1 | 0 | 3 |
| LDL cholesterol calculation, Grade 2 | 1 | 0 |
| LDL cholesterol calculation, Grade 3 | 0 | 0 |
| LDL cholesterol calculation, Grade 4 | 0 | 0 |
| Lipase, Grade 1 | 3 | 2 |
| Lipase, Grade 2 | 0 | 3 |
| Lipase, Grade 3 | 0 | 0 |
| Lipase, Grade 4 | 0 | 1 |
| Phosphate, Grade 1 | 5 | 5 |
| Phosphate, Grade 2 | 10 | 7 |
| Phosphate, Grade 3 | 1 | 1 |
| Phosphate, Grade 4 | 0 | 0 |
| Potassium, Grade 1 | 8 | 3 |
| Potassium, Grade 2 | 0 | 2 |
| Potassium, Grade 3 | 0 | 0 |
| Potassium, Grade 4 | 1 | 1 |
| Sodium, Grade 1 | 22 | 9 |
| Sodium, Grade 2 | 3 | 3 |
| Sodium, Grade 3 | 1 | 0 |
| Sodium, Grade 4 | 0 | 0 |
Blood samples for assessment of hematology parameters were collected at indicated time points. Hematology assessments included hemoglobin, leukocytes, neutrophils and platelets. Data for number of participants who experienced maximum post-Baseline emergent hematology toxicities were summarized. Maximum post-Baseline emergent hematology toxicities were graded using DAIDS toxicity grading for HIV-infected participants as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life-threating). Higher grade indicates more severity.
| Participants | DTG 50 mg | EFV 600 mg |
|---|---|---|
| Hemoglobin, Grade 1 | 2 | 1 |
| Hemoglobin, Grade 2 | 0 | 0 |
| Hemoglobin, Grade 3 | 0 | 0 |
| Hemoglobin, Grade 4 | 0 | 0 |
| Leukocytes, Grade 1 | 4 | 1 |
| Leukocytes, Grade 2 | 0 | 0 |
| Leukocytes, Grade 3 | 0 | 1 |
| Leukocytes, Grade 4 | 0 | 1 |
| Neutrophils, Grade 1 | 6 | 3 |
| Neutrophils, Grade 2 | 2 | 1 |
| Neutrophils, Grade 3 | 1 | 0 |
| Neutrophils, Grade 4 | 1 | 2 |
| Platelets, Grade 1 | 2 | 1 |
| Platelets, Grade 2 | 0 | 0 |
| Platelets, Grade 3 | 1 | 0 |
| Platelets, Grade 4 | 0 | 0 |
Blood samples for assessment of hematology parameters were collected at indicated time points. Hematology assessments included hemoglobin, leukocytes, neutrophils and platelets. Data for number of participants who experienced maximum post-Baseline emergent hematology toxicities were summarized. Maximum post-Baseline emergent hematology toxicities were graded using DAIDS toxicity grading for HIV-infected participants as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life-threating). Higher grade indicates more severity.
| Participants | DTG 50 mg | EFV 600 mg |
|---|---|---|
| Hemoglobin, Grade 1 | 2 | 1 |
| Hemoglobin, Grade 2 | 1 | 0 |
| Hemoglobin, Grade 3 | 0 | 0 |
| Hemoglobin, Grade 4 | 0 | 0 |
| Leukocytes, Grade 1 | 5 | 3 |
| Leukocytes, Grade 2 | 1 | 1 |
| Leukocytes, Grade 3 | 0 | 1 |
| Leukocytes, Grade 4 | 0 | 1 |
| Neutrophils, Grade 1 | 4 | 2 |
| Neutrophils, Grade 2 | 5 | 3 |
| Neutrophils, Grade 3 | 2 | 0 |
| Neutrophils, Grade 4 | 2 | 3 |
| Platelets, Grade 1 | 0 | 2 |
| Platelets, Grade 2 | 1 | 0 |
| Platelets, Grade 3 | 2 | 0 |
| Platelets, Grade 4 | 0 | 0 |
Samples for lipid measurements were obtained in a fasted state at Baseline, Week 24 and Week 48. The parameters assessed during the lipid profile were total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, triglycerides. Baseline was defined as the last pre-treatment value observed (typically from Day 1 visit). Percent change from Baseline for a parameter was calculated as the observed value minus the Baseline value divided by Baseline value multiplied by 100. Data for fasting lipid parameters has been summarized.
| Percent change | DTG 50 mg | EFV 600 mg |
|---|---|---|
| Cholesterol, Week 24, n=58, 40 | 6.314 ± 20.7036 | 16.443 ± 22.0445 |
| Cholesterol, Week 48, n=47, 34 | -0.375 ± 21.4890 | 17.371 ± 20.6312 |
| HDL Cholesterol, Week 24, n=58, 40 | 39.002 ± 53.5060 | 39.174 ± 49.1087 |
| HDL Cholesterol, Week 48, n=47, 34 | 24.987 ± 48.2471 | 45.423 ± 52.9949 |
| LDL Cholesterol, Week 24, n=58, 40 | 4.315 ± 31.7095 | 13.487 ± 36.2511 |
| LDL Cholesterol, Week 48, n=47, 34 | -2.957 ± 31.9910 | 9.132 ± 41.1942 |
| Triglycerides, Week 24, n=58, 40 | -22.744 ± 33.4148 | 16.934 ± 118.7319 |
| Triglycerides, Week 48, n=47, 34 | -18.402 ± 39.0227 | 13.175 ± 57.0389 |
Samples for lipid measurements were obtained in a fasted state at Baseline, Week 24 and Week 48. The parameter assessed during the lipid profile was total cholesterol/HDL ratio. Baseline was defined as the last pre-treatment value observed (typically from Day 1 visit). Change from baseline for a parameter was calculated as the observed value minus the Baseline value.
| Ratio of total cholesterol to HDL | DTG 50 mg | EFV 600 mg |
|---|---|---|
| Total cholesterol/HDL ratio, Week 24, n=58, 40 | -16.292 ± 22.7982 | 36.562 ± 315.0478 |
| Total cholesterol/HDL ratio, Week 48, n=47, 34 | -11.949 ± 27.5044 | -11.051 ± 28.3183 |
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Data for percentage of participants who permanently discontinued study treatment due to any AE over 52 weeks has been summarized.
| Percentage of participants | DTG 50 mg | EFV 600 mg |
|---|---|---|
| Percentage of Participants Who Permanently Discontinued Study Treatment Due to AEs - Randomized Phase | 0 | 5 |
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Data for percentage of participants who permanently discontinued study treatment due to any AE from Week 52 to Week 252 has been summarized.
| Percentage of participants | DTG 50 mg | EFV 600 mg |
|---|---|---|
| Percentage of Participants Who Permanently Discontinued Study Treatment Due to AEs - OLE Phase | 4 | 0 |
Participants were monitored for signs and symptoms of TB-assoc. IRIS. Participants with IRIS symptoms in any AE or HIV assoc. conditions were classified by Endpoint Adjudication Committee in following four categories: met criteria for TB-assoc. IRIS, possibly met criteria for TB-assoc. IRIS, suspected TB-assoc. IRIS but not possible to adjudicate and No TB associated IRIS. They were further graded from Grades 1 to 4 using DAIDS. Higher grade indicates more severity. The preliminary requirements to meet TB-assoc. IRIS criteria were diagnosis of TB and initial response to TB treatment (stabilized or improved condition of participant in presence of TB treatment before starting ART). The clinical criteria was onset of IRIS signs and symptoms related to TB should occur within first 3 months of starting, restarting or changing ART regimen for treatment failure. Number of participants who sent to the adjudication committee and analyzed were presented.
| Participants | DTG 50 mg | EFV 600 mg |
|---|---|---|
| Met criteria for TB-assoc. IRIS, Grade 1 | 1 | 0 |
| Met criteria for TB-assoc. IRIS, Grade 2 | 2 | 3 |
| Met criteria for TB-assoc. IRIS, Grade 3 | 1 | 0 |
| Met criteria for TB-assoc. IRIS, Grade 4 | 0 | 1 |
| Possibly met criteria for TB-assoc. IRIS, Grade 1 | 0 | 0 |
| Possibly met criteria for TB-assoc. IRIS, Grade 2 | 0 | 0 |
| Possibly met criteria for TB-assoc. IRIS, Grade 3 | 0 | 0 |
| Possibly met criteria for TB-assoc. IRIS, Grade 4 | 0 | 0 |
| Suspected TB-assoc. IRIS unable to adjudicate, Grade 1 | 0 | 0 |
| Suspected TB-assoc. IRIS unable to adjudicate, Grade 2 | 0 | 0 |
| Suspected TB-assoc. IRIS unable to adjudicate, Grade 3 | 0 | 0 |
| Suspected TB-assoc. IRIS unable to adjudicate, Grade 4 | 0 | 0 |
| No TB associated IRIS | 5 | 8 |
Whole venous blood samples were obtained from each participant until Week 52 for potential viral genotypic and phenotypic analyses. Genotypic and phenotypic testing was conducted for participants meeting confirmed virologic withdrawal criteria, i.e., confirmed HIV-1 RNA \>=400 copies/milliliter from Week 24 onwards. Genotypic and phenotypic analyses was carried out by Monogram Biosciences using, but not limited to, their Standard Phenosense and GenoSure testing methods for protease (PRO), reverse transcriptase (RT), and integrase assays. Data for number of participants with treatment-emergent genotypic resistance mutations have been presented for the RT region on codons G190G, K101K, K103K, K65K, V106V and Y181Y.
| Participants | DTG 50 mg | EFV 600 mg |
|---|---|---|
| G190G (wild type) | 2 | 0 |
| G190G/A | 0 | 1 |
| K101K (wild type) | 2 | 0 |
| K101K/E | 0 | 1 |
| K103K (wild type) | 2 | 0 |
| K103K/N | 0 | 1 |
| K65K (wild type) | 2 | 0 |
| K65R | 0 | 1 |
| V106V (wild type) | 2 | 0 |
| V106M | 0 | 1 |
| Y181Y (wild type) | 2 | 0 |
| Y181Y/C | 0 | 1 |
Phenotypic susceptibility to all licensed antiretroviral drugs, including DTG and EFV were determined using PhenoSense HIV assays from Monogram Inc. Clinical cutoffs or biological cutoffs by PhenoSense were used to define the phenotypic susceptibility of background treatment and were interpreted as fold change \> clinical lower cut-off or biologic cut-off as resistance, fold change \<=clinical lower cut-off or biologic cut-off as sensitive, and fold change \> clinical higher cut-off as resistance, fold change \<=clinical higher cut-off and \> clinical lower cut-off as partially sensitive, and fold change \<=clinical lower cut-off as sensitive. Data has been presented for participants with treatment-emergent phenotypic resistance.
| Participants | DTG 50 mg | EFV 600 mg |
|---|---|---|
| Dolutegravir, Sensitive, n=1,1 | 1 | 1 |
| Dolutegravir, Partially sensitive, n=1,1 | 0 | 0 |
| Dolutegravir, Resistance, n=1,1 | 0 | 0 |
| Elvitegravir, Sensitive, n=1,1 | 1 | 1 |
| Elvitegravir, Resistance, n=1,1 | 0 | 0 |
| Raltegravir, Sensitive, n=1,1 | 1 | 1 |
| Raltegravir, Resistance, n=1,1 | 0 | 0 |
| Delavirdine, Sensitive, n=2,1 | 2 | 1 |
| Delavirdine, Resistance, n=2,1 | 0 | 0 |
| Efavirenz, Sensitive, n=2,1 | 2 | 0 |
| Efavirenz, Resistance, n=2,1 | 0 | 1 |
| Etravirine, Sensitive, n=2,1 | 2 | 1 |
| Etravirine, Partially sensitive, n=2,1 | 0 | 0 |
| Etravirine, Resistance, n=2,1 | 0 | 0 |
| Nevirapine, Sensitive, n=2,1 | 2 | 0 |
| Nevirapine, Resistance, n=2,1 | 0 | 1 |
| Rilpivirine, Sensitive, n=2,1 | 2 | 1 |
| Rilpivirine, Resistance, n=2,1 | 0 | 0 |
| Abacavir, Sensitive, n=2,1 | 2 | 1 |
| Abacavir, Partially sensitive, n=2,1 | 0 | 0 |
| Abacavir, Resistance, n=2,1 | 0 | 0 |
| Didanosine, Sensitive, n=2,1 | 2 | 0 |
| Didanosine, Partially sensitive, n=2,1 | 0 | 0 |
| Didanosine, Resistance, n=2,1 | 0 | 1 |
| Emtricitabine, Sensitive, n=2,1 | 2 | 0 |
| Emtricitabine, Resistance, n=2,1 | 0 | 1 |
| Lamivudine, Sensitive, n=2,1 | 2 | 0 |
| Lamivudine, Resistance, n=2,1 | 0 | 1 |
| Stavudine, Sensitive, n=2,1 | 2 | 1 |
| Stavudine, Resistance, n=2,1 | 0 | 0 |
| Tenofovir, Sensitive, n=2,1 | 2 | 0 |
| Tenofovir, Partially sensitive, n=2,1 | 0 | 1 |
| Tenofovir, Resistance, n=2,1 | 0 | 0 |
| Zidovudine, Sensitive, n=2,1 | 2 | 1 |
| Zidovudine, Resistance, n=2,1 | 0 | 0 |
| Atazanavir, Sensitive, n=2,1 | 2 | 1 |
| Atazanavir, Resistance, n=2,1 | 0 | 0 |
| Darunavir, Sensitive, n=2,1 | 2 | 1 |
| Darunavir, Partially sensitive, n=2,1 | 0 | 0 |
| Darunavir, Resistance, n=2,1 | 0 | 0 |
| Fosamprenavir, Sensitive, n=2,1 | 2 | 1 |
| Fosamprenavir, Partially sensitive, n=2,1 | 0 | 0 |
| Fosamprenavir, Resistance, n=2,1 | 0 | 0 |
| Indinavir,Sensitive, n=2,1 | 2 | 1 |
| Indinavir, Resistance, n=2,1 | 0 | 0 |
| Lopinavir, Sensitive, n=2,1 | 2 | 1 |
| Lopinavir, Partially sensitive, n=2,1 | 0 | 0 |
| Lopinavir, Resistance, n=2,1 | 0 | 0 |
| Nelfinavir, Sensitive, n=2,1 | 2 | 1 |
| Nelfinavir, Resistance, n=2,1 | 0 | 0 |
| Ritonavir, Sensitive, n=2,1 | 2 | 1 |
| Ritonavir, Partially sensitive, n=2,1 | 0 | 0 |
| Ritonavir, Resistance, n=2,1 | 0 | 0 |
| Saquinavir, Sensitive, n=2,1 | 2 | 1 |
| Saquinavir, Partially sensitive, n=2,1 | 0 | 0 |
| Saquinavir, Resistance, n=2,1 | 0 | 0 |
| Tipranavir, Sensitive, n=2,1 | 2 | 1 |
| Tipranavir, Partially sensitive, n=2,1 | 0 | 0 |
| Tipranavir, Resistance, n=2,1 | 0 | 0 |
Collected over Serious adverse events (SAEs) and non-SAEs were collected up to Week 52 for Randomized Phase and from Week 52 to Week 252 for OLE Phase.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DTG 50 mg- Randomized Phase | 0/69 (0%) | 5/69 (7.2%) | 38/69 (55.1%) |
| EFV 600 mg- Randomized Phase | 0/44 (0%) | 5/44 (11.4%) | 33/44 (75%) |
| DTG 50 mg- OLE Phase | 1/47 (2.1%) | 5/47 (10.6%) | 36/47 (76.6%) |
| EFV 600 mg- OLE Phase | 0/19 (0%) | 2/19 (10.5%) | 16/19 (84.2%) |
| Event | DTG 50 mg- Randomized Phase | EFV 600 mg- Randomized Phase | DTG 50 mg- OLE Phase | EFV 600 mg- OLE Phase |
|---|---|---|---|---|
| Psoas abscessInfections and infestations | 0/69 | 0/44 | 0/47 | 1/19 |
| HeadacheNervous system disorders | 0/69 | 0/44 | 0/47 | 1/19 |
| PneumoniaInfections and infestations | 0/69 | 1/44 | 0/47 | 0/19 |
| Patella fractureInjury, poisoning and procedural complications | 0/69 | 1/44 | 0/47 | 0/19 |
| Immune reconstitution inflammatory syndromeImmune system disorders | 0/69 | 1/44 | 0/47 | 0/19 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/69 | 1/44 | 0/47 | 0/19 |
| Suicidal ideationPsychiatric disorders | 0/69 | 1/44 | 0/47 | 0/19 |
| Acute kidney injuryRenal and urinary disorders | 0/69 | 1/44 | 0/47 | 0/19 |
| Lower limb fractureInjury, poisoning and procedural complications | 0/69 | 0/44 | 1/47 | 0/19 |
| Foetal deathPregnancy, puerperium and perinatal conditions | 0/69 | 0/44 | 1/47 | 0/19 |
| Event | DTG 50 mg- Randomized Phase | EFV 600 mg- Randomized Phase | DTG 50 mg- OLE Phase | EFV 600 mg- OLE Phase |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 5/69 | 8/44 | 12/47 | 5/19 |
| DiarrhoeaGastrointestinal disorders | 3/69 | 10/44 | 4/47 | 3/19 |
| HeadacheNervous system disorders | 9/69 | 6/44 | 5/47 | 4/19 |
| Lower respiratory tract infectionInfections and infestations | 9/69 | 3/44 | 4/47 | 3/19 |
| DizzinessNervous system disorders | 3/69 | 6/44 | 0/47 | 0/19 |
| GastroenteritisInfections and infestations | 1/69 | 5/44 | 3/47 | 2/19 |
| FuruncleInfections and infestations | 0/69 | 0/44 | 3/47 | 2/19 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/69 | 0/44 | 1/47 | 2/19 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 0/69 | 0/44 | 0/47 | 2/19 |
| DysuriaRenal and urinary disorders | 0/69 | 0/44 | 0/47 | 2/19 |
| Age, Continuous(Years) | DTG 50 mg | EFV 600 mg | Total |
|---|---|---|---|
| Mean | 34.6 ± 10.25 | 33.1 ± 7.56 | 34.0 ± 9.29 |
| Sex: Female, Male(Participants) | DTG 50 mg | EFV 600 mg | Total |
|---|---|---|---|
| Female | 30 | 16 | 46 |
| Male | 39 | 28 | 67 |
| Race/Ethnicity, Customized(Participants) | DTG 50 mg | EFV 600 mg | Total |
|---|---|---|---|
| African American/African Heritage | 47 | 28 | 75 |
| American Indian or Alaska Native | 11 | 4 | 15 |
| Asian - South East Asian Heritage | 0 | 2 | 2 |
| White - Arabic/North African Heritage | 1 | 0 | 1 |
| White - White/Caucasian/European Heritage | 9 | 9 | 18 |
| Mixed Race | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2015 to primary completion in Nov 2017, 33 months.
Results were first posted in Feb 2019, 1 year 3 months after primary completion.
Of 41 industry-sponsored phase 3 interventional studies under Infections, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 33. This study's 33 months is above that.
Counting every sponsor, half of 75 studies reached it within 30 months; a quarter within 17 and three quarters within 53.
Infections covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dolutegravir